Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series
ConclusionsRetreatment with ipi + nivo may be considered an option in carefully selected, well-informed patients. More research is required to delineate the benefits and risks with this approach.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Immunotherapy | Melanoma | Skin Cancer | Toxicology | Yervoy